Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of the management of sickle cell disease patients treated with hydroxycarbamide
2021-002094-26Phase 4Active
- Sponsor
- Strasbourg University Hospital
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroxyurea in sickle cell disease (SCD) (2 arms), sponsored by Strasbourg University Hospital. Started Apr 2022; status: active.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2021-002094-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002094-26.